CliffBio
small molecule

DAYBUE STIX

TROFINETIDE

Loss of exclusivityJanuary 2043latest FDA-listed patent expiry
CompanyAcadia Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAYBUE STIX
Active ingredientTROFINETIDE
Strength8000MG/PACKET
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2025
Marketing statusRX

Listed patents

PatentExpiresType
11827600*PEDJanuary 2043—
12492167*PEDJanuary 2043—
12492167July 2042substance, product
11827600July 2042substance, product
11370755*PEDFebruary 2041—
11370755August 2040substance, product
9212204*PEDJuly 2032—
9212204January 2032use U-3556

Regulatory exclusivity

CodeExpires
PEDSeptember 2030
ODE*March 2030
PEDSeptember 2028
NCEMarch 2028

More from Acadia Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DAYBUE STIX patent cliff — loss of exclusivity January 2043 | CliffBio